Capricor Therap (CAPR) Stock Price, Quote & News

Company Profile

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial t...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 727 1755

Website: www.capricor.com

Address:

10865 Road to the Cure, Suite 150, San Diego, United States

scaredmoneymakenomoney Oct. 26 at 9:39 PM

$CAPR gonna slap that ask first thing when markets open

1 · Reply

Cote0924 Oct. 26 at 8:21 PM

$CAPR After almost 6 years invested in capricor this may be my last SP guess….. $12-$14 run up into data release When LEVF and PUL both meet endpoints….PM price is $25 and hits $40 intra day Long and strong my friends. Godspeed to the boys who need deramiocel 🫡🫡

1 · Reply

dnfrs Oct. 26 at 8:01 PM

$CAPR If Novartis paid $12 Billion to buyout Avidity...what is Capricor worth? Deramiocel has a much more important impact on ALL DMD boys...and the StealthX platform has application to literally hundreds of vaccine, cancer and immunotherapy applications.

2 · Reply

PhantomZ Oct. 26 at 6:33 PM

$CAPR https://investors.aviditybiosciences.com/2025-10-26-Avidity-Biosciences-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG

1 · Reply

Ag035 Oct. 26 at 5:40 PM

$CAPR Crazy times, their current MC is 6.7 billion. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-avidity-biosciences-12-billion-2025-10-26/

1 · Reply

The_Fact_ster Oct. 26 at 5:25 PM

$CAPR LMAO still living rent free in WBinthehouse's head

1 · Reply

dnfrs Oct. 26 at 5:17 PM

$CAPR The recent corporate presentation on slide 37 reads... "Active NIH Collaboration Underway Exosome-Based Multivalent Vaccine  Capricor’s StealthX vaccine was selected by Project NextGen • Aim is to advance a pipeline of innovative vaccines which may provide broader and more durable protection against COVID-19 and other potential infectious threats  The National Institute of Allergy and Infectious Diseases (NIAID) is conducting and funding the Phase 1 clinical trial • Study is underway with topline data expected in ~Q1 2026 • Capricor is supplying investigational product  If NIAID finds our vaccine meets its criteria for safety and efficacy, they may consider our program for a funded Phase 2 ClinicalTrials.gov ID: NCT07095231 " This all good news and I have to wonder if the potentially fully funded phase 2 might be large enough to be pivotal? If the Feds urgently want to get something better and safer than mRNA vaccines StealthX vaccines can answer their needs !

0 · Reply

snowboy Oct. 26 at 4:31 PM

$CAPR Busy couple of weeks upcoming for Linda and team. Please remember that the gene nerds at $SRPT and others will be needed for true cures. Once concept of exosome-based treatment proved, work will start on using StealthX platform to float gene therapies to muscles so that the damned AAV vectors and their incipient side effects can be ditched. For instance, $QURE will be able to float Huntingdon gene fix to brain using IV administered exosome carrier, eliminating manual placement in brain via surgery. I am remaining incredibly long investor from here... $40 billion MC or buyout. 30 minutes to kickoff. See ya at Thanksgiving.

0 · Reply

lymond Oct. 26 at 3:41 PM

$CAPR Looks like we'll be getting a video from MRC soon, "sharing our belief that the treatment is working." https://musculardystrophynews.com/columns/im-giving-everything-have-duchenne-md-own-way

3 · Reply

WBinthehouse Oct. 26 at 3:36 PM

$CAPR I see Fud posting BP should buy NS, but NS only has rights to Deramiocel for DMD only. So not really getting all of CAPR if anyone buys NS. Just proves some are not totally in the know.

1 · Reply

Capricor Therapeutics, Inc. Long-Term Shareholder Announcement: Johnson Fistel Encourages Investors to Reach Out For More Information About Continuing Investigation

Sep 29, 2025, 3:51 PM EDT - 27 days ago

Capricor: Post-CRL Path To DMD Cardiomyopathy Approval In 2026

Sep 29, 2025, 9:08 AM EDT - 27 days ago

Capricor Therapeutics: A Buy Ahead Of Phase 3 Topline And Clarified Regulatory Pathway

Sep 25, 2025, 11:07 AM EDT - 4 weeks ago

Capricor Therapeutics, Inc. - Special Call

Sep 25, 2025, 7:15 AM EDT - 4 weeks ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting

Sep 13, 2025, 11:35 AM EDT - 6 weeks ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Sep 9, 2025, 9:20 AM EDT - 6 weeks ago

Capricor Therapeutics Responds to FDA Posting of Complete Response Letter (CRL) for Deramiocel

Aug 28, 2025, 7:05 PM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 22, 2025, 10:20 AM EDT - 2 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Capricor Therapeutics

Aug 18, 2025, 11:35 AM EDT - 2 months ago

Capricor Therapeutics, Inc. (CAPR) Q2 2025 Earnings Conference Call Transcript

Aug 8, 2025, 8:30 AM EDT - 2 months ago

Capricor Therapeutics Announces Type A Meeting Scheduled with U.S. FDA

Aug 6, 2025, 9:00 AM EDT - 2 months ago

Capricor Therapeutics to Present Second Quarter 2025 Financial Results and Recent Corporate Update on August 13

Jul 31, 2025, 8:45 AM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit - CAPR

Jul 30, 2025, 4:27 PM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 15, 2025 in Capricor Therapeutics, Inc. Lawsuit – CAPR

Jul 30, 2025, 11:07 AM EDT - 3 months ago

What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?

SRPT CABA NGNE NTLA QURE RCKT

Jul 17, 2025, 4:46 PM EDT - 3 months ago

BREAKING: Capricor Therapeutics Sued For Securities Fraud; Investors Should Contact Block & Leviton to Potentially Recover Losses

Jul 16, 2025, 7:55 PM EDT - 3 months ago

Bragar Eagel & Squire, P.C. is Investigating Capricor Therapeutics, Inc. on Behalf of Capricor Stockholders and Encourages Investors to Contact the Firm

Jul 14, 2025, 4:14 PM EDT - 3 months ago

Wolf Popper LLP Announces Investigation on Behalf of Capricor Therapeutics, Inc. Investors

Jul 14, 2025, 7:43 AM EDT - 3 months ago

Capricor Therapeutics: Buying Opportunity Following FDA's Complete Response Letter

Jul 11, 2025, 4:53 PM EDT - 3 months ago

Capricor Therapeutics, Inc. (NASDAQ: CAPR) Securities Fraud Investigation; CAPR Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Jul 11, 2025, 9:03 AM EDT - 3 months ago

Capricor's Lead Duchenne Therapy Hits FDA Regulatory Roadblock

Jul 11, 2025, 8:20 AM EDT - 3 months ago

Frequency Electronics, Capricor Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

FEIM

Jul 11, 2025, 6:36 AM EDT - 3 months ago

US FDA declines to approve Capricor's muscle disorder therapy

Jul 11, 2025, 6:30 AM EDT - 3 months ago

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA for Duchenne Muscular Dystrophy

Jun 24, 2025, 2:51 PM EDT - 4 months ago

FDA Skips Advisory Committee For Capricor's Duchenne Cell Therapy

Jun 24, 2025, 9:16 AM EDT - 4 months ago

US FDA will not convene expert panel for Capricor Therapeutics' DMD cell therapy

Jun 23, 2025, 12:46 PM EDT - 4 months ago

Why Is Capricor Therapeutics Stock Trading Lower On Monday?

Jun 20, 2025, 3:11 PM EDT - 4 months ago

Capricor Reports 4-Year Data For Deramiocel, Shows Sustained Benefit In Duchenne Patients

Jun 20, 2025, 9:25 AM EDT - 4 months ago

Capricor Therapeutics Announces Positive 4-Year Data from HOPE-2 Open-Label Extension Study of Deramiocel in Duchenne Muscular Dystrophy

scaredmoneymakenomoney Oct. 26 at 9:39 PM

$CAPR gonna slap that ask first thing when markets open

1 · Reply

Cote0924 Oct. 26 at 8:21 PM

1 · Reply

dnfrs Oct. 26 at 8:01 PM

2 · Reply

PhantomZ Oct. 26 at 6:33 PM

$CAPR https://investors.aviditybiosciences.com/2025-10-26-Avidity-Biosciences-Enters-into-Agreement-to-be-Acquired-by-Novartis-AG

1 · Reply

Ag035 Oct. 26 at 5:40 PM

$CAPR Crazy times, their current MC is 6.7 billion. https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-acquire-avidity-biosciences-12-billion-2025-10-26/

1 · Reply

The_Fact_ster Oct. 26 at 5:25 PM

$CAPR LMAO still living rent free in WBinthehouse's head

1 · Reply

dnfrs Oct. 26 at 5:17 PM

0 · Reply

snowboy Oct. 26 at 4:31 PM

0 · Reply

lymond Oct. 26 at 3:41 PM

$CAPR Looks like we'll be getting a video from MRC soon, "sharing our belief that the treatment is working." https://musculardystrophynews.com/columns/im-giving-everything-have-duchenne-md-own-way

3 · Reply

WBinthehouse Oct. 26 at 3:36 PM

$CAPR I see Fud posting BP should buy NS, but NS only has rights to Deramiocel for DMD only. So not really getting all of CAPR if anyone buys NS. Just proves some are not totally in the know.

1 · Reply

dnfrs Oct. 26 at 3:33 PM

$CAPR In a few weeks we should have both the phase 3 deramiocel topline LVEF and PUL data. I expect both to be successful. I am also hopeful that we will get a Quarterly Report update on the NIAID funded StealthX exosome Covid vaccine trial and at least an overview of the progress on the entire StealthX platform ! A lot of good news coming IMO !

0 · Reply

neelsen01 Oct. 26 at 1:06 PM

$CAPR Cash floor seen at around $3/share…

1 · Reply

neelsen01 Oct. 26 at 1:05 PM

$CAPR Looking to sell the Nov 21 $2.50 puts for $0.25 if IV increases…

1 · Reply

jamestrade07 Oct. 26 at 12:34 PM

$CAPR within less than a week from the time they unblind the data they should have a pretty good idea if the trail was successful or not. The fact they have added /or republished 4 new jobs this week is encouraging and if they will add more jobs in the coming days we can almost certainly assume they are happy with the results. I'm banking on LEVF hitting stat sig and PUL narrowly hitting or missing. If LEVF hits then the FDA will most certainly approve the drug and if PUL norrowly misses they can reach an agreement with the FDA to keep hope 3 OLE running for another year and than submitting the PUL 2 data next year. If this data will be stat sig they will be able to update the label.

1 · Reply

Stormfury66 Oct. 26 at 12:26 PM

$CAPR PART 2 LVEF End point hits 70-80% PUL2.0 60-70% = FDA Approval 300%+ squeeze LONG TERM INVESTORS HOLD & trust Linda & team NEWBIES do ur own DD & if you decide to get on board with us “ good move “ It’s been an extremely agonizing ride over the years & I know some doubt has crept in .. but this is it .. ALL on the line for EVERYONE but just think about what it will mean to the children as it signifies HOPE .. as in HOPE-3 to cross the finish line . One of the most undervalued stock in the bio industry

0 · Reply

mmc100 Oct. 26 at 12:25 PM

$CAPR

0 · Reply

Stormfury66 Oct. 26 at 12:16 PM

$CAPR Im with @LineBacker04 .. LVEF has a very good probability of hitting its endpoints . Even if PUL misses ( odds favor it won’t ) but if it does miss & LVEF hits for the heart FDA approval will take place , just the labeling will not be as expansive . Earnings date is Nov 12th , this could be moved around some pending data release . Regardless the 2nd week of Nov & on CAPR will experince extreme volatility as Bulls vs Bear cases will run rampant . My stance as a HEAVY investor & following CAPR for many years & from everything I’ve had heard from Linda & FDA stating they are aligned with CAPR & have FLEXIBILITY in determining the approval & allowing resubmission with Hope-3 data , I strongly believe we will cross the long awaited finish line , Linda came on board in 2005 with her expertise in cardiac working to slow down heart deterioration , thus allowing those suffering from DMD a stronger & living a longer duration & actually enjoying life . All this will mean a breakthrough

1 · Reply

Stormfury66 Oct. 26 at 11:37 AM

$CAPR Exact date is hard to say , however data release is due Mid this quarter that would place it ard NOV 15th ..

0 · Reply

great_investment_thesis Oct. 26 at 11:10 AM

$CAPR I'm new here, so I'll be brief, as I respect the knowledge of the long-time holders. I just invested a significant amount. My thesis is simple: LVEF data is 100% hitting. That translates to 3X. Don't care about PUL 2.0 (total bonus). The LVEF P-value from HOPE-2 is all that matters, and that's rock solid.

0 · Reply

LiquidThetaLEAPS Oct. 26 at 8:31 AM

LiquidTheta® LEAPS LIVE Actionable Alert Asset: $CAPR Current Share Price: $6.20 Contracts: $CAPR January 15, 2027 $8 Calls Scale in: $2.93- $3.58 Scale out: $4.55-$5.85 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com

0 · Reply

MoneyGroupLLC Oct. 26 at 6:38 AM

Enter: $CAPR Calls Strike Price: $8 Expiry Date: NOV 21 2025 Buy in Price: $1.70 - $2.10 Sell Price: $3.86 Profit : +127% (Turn every $1 into $2.27) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us/

0 · Reply

Its_Never_Too_Late Oct. 26 at 4:20 AM

$CAPR We are one day closer to potentially seeing deramiocel being shut down as a program. Once we see the results of HOPE-3 we will know. Im betting with my many decades of biotechnology inveating experience that HOPE-3 MISSES ALL endpoints. $CAPR

1 · Reply

Market Cap	283.45M
Revenue (ttm)	22.27M
Net Income (ttm)	-40.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-181.72%
Debt to Equity Ratio	0.00

Volume	1,116,300
Avg Vol	1,263,490
Day's Range	N/A - N/A
Shares Out	45.72M
Stochastic %K	22%
Beta	0.68
Analysts	Strong Sell
Price Target	$20.60